The deal, which could be worth up to $870 million overall, will give Lilly access to a delivery technology that may help ...

Camurus licensed its FluidCrystal drug delivery tech to Eli Lilly for global development of long-acting incretin therapies ...

Eli Lilly joins up with Camurus to make long-acting versions of the pharma's obesity and diabetes drugs, joining the industry ...

Camurus (NASDAQ STO: CAMX) and Eli Lilly and Company ("Lilly") have entered a collaboration and license agreement, granting Lilly exclusive, worldwide rights to the research, development, manufacture, ...

On Tuesday, Camurus (OTC:CAMRF) and Eli Lilly and Company (NYSE: LLY) entered into a collaboration and license agreement.

Eli Lilly is counting on Camurus and its long-acting delivery technology to help take its portfolio of obesity and diabetes drugs to the next level with a licensing deal worth up to $870 million.

US pharma major Eli Lilly (NYSE: LLY) has struck a deal worth up to $870 million with Swedish biotech Camurus (Nasdaq ...

LUND, Sweden, July 15, 2024 /PRNewswire/ -- Camurus (NASDAQ: CAMX) (STO: CAMX) today announced positive, final, topline results from the 52-week Phase 3 open-label ACROINNOVA 2 (NCT04125836 ...

Introduction & Market Context Camurus AB (STO:CAMX) presented its first quarter 2025 results on May 15, revealing strong financial performance despite challenging market conditions. The Swedish ...

(RTTNews) - Camurus (CAMX), Friday announced that the European Medicines Agency's Committee for Medicinal Products for Human Use has issued a positive opinion recommending market authorization of ...

Camurus eligible to receive up to $870 million in potential development and sales milestone payments and mid-single-digit royalty "We are pleased to enter into this collaboration with Lilly to ...

Camurus maintained its full-year 2025 guidance, projecting revenue between SEK 2.7-3.0 billion (45-61% growth versus 2024) and profit before tax of SEK 0.9-1.2 billion (63-117% growth versus 2024).